350 Patients Have Been Treated—Mesoblast’s Pain Data Come Next
Mesoblast (MESO) has completed patient treatment in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, treating 350 patients. The trial evaluates rexlemestrocel-L and targets a primary endpoint of durable pain reduction at 12 months. Top-line results …